Saturday 17 October 2026 Export HYPR’s income statement to Excel — free account

Hyperfine, Inc.

Hyperfine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 5.22% from fiscal 2024. In the quarter to June 2026, revenue grew 44.8%, EPS grew 25.0% and free cash flow grew 13.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

0.75 0.03 −3.85%

Follow HYPR

Alert me

Market cap: $82.7M
P/E: 0.0×
Fwd P/E: −4.0×
Dividend yield: —
F-score: 4/9
Altman Z: −6.11
Beneish M: −3.54
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.09

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	1	2	—	2	—	—	2	—	—

Insider Ownership 14.87%

Capital & Financial Ratios $m

Market Cap 82.73

Revenue 16.54

Net Income (34.85)

Free Cash Flow (27.53)

Net Debt (31.53)

Current Ratio 6.15

Debt/Equity 0.36

P/E ratio 0.00

Fwd P/E (3.98)

P/S ratio 4.53

P/B ratio 2.04

Past 5Y EPS Growth —

This Y EPS Growth 20.93%

Next Y EPS Growth 5.88%

Next Y revenue growth 48.71%

Next 5Y EPS Growth 11.31%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 2.91%

10-year low 10-year high

P/B against its own 10 years 64.75%

10-year low 10-year high

EV/Sales against its own 10 years 38.61%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	76	38	36	45
Receivables	4	8	7	6
Inventory	7	6	7	7
Other	—	—	—	—
	89	54	51	59

	2023	2024	2025	Q'26
Payables	1	2	4	2
ST’ Debt	—	—	—	—
Other	1	0	1	1
	9	9	12	10

Compound Annual Growth %

	10y	5y	3y
Sales	—	115.18%	25.79%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(30.80%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	4	4	—	—	—
’25	2	3	3	5	14
’24	3	4	4	2	13
’23	3	3	2	3	11
’22	2	2	2	1	7
’21	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(7)	—	—	—
’25	(9)	(8)	(6)	(5)	(28)
’24	(13)	(9)	(9)	(8)	(39)
’23	(13)	(10)	(9)	(10)	(42)
’22	(27)	(17)	(13)	(15)	(72)
’21	(7)	(12)	(10)	(18)	(47)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(7)	—	—	—
’25	(10)	(8)	(6)	(5)	(29)
’24	(13)	(9)	(9)	(8)	(39)
’23	(14)	(10)	(9)	(10)	(43)
’22	(28)	(17)	(13)	(16)	(73)
’21	(8)	(12)	(11)	(19)	(50)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.09)	(0.09)	—	—	—
’25	(0.12)	(0.12)	(0.14)	(0.06)	(0.43)
’24	(0.14)	(0.14)	(0.14)	(0.14)	(0.56)
’23	(0.17)	(0.15)	(0.15)	(0.15)	(0.62)
’22	(0.34)	(0.33)	(0.19)	(0.19)	(1.04)
’21	(4.86)	(8.80)	(8.66)	(2.73)	(17.57)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	6.85	0.68	0.77	0.76	0.53	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	16.61	7.50	3.28	1.39	2.22
People
People	Employees	—	—	—	—	2	193	136	131	111	102
	Revenue/emp, $m	—	—	—	—	0.15	0.01	0.05	0.08	0.12	0.13
Income, $m
Income, $m	Revenue	—	—	—	—	0	1	7	11	13	14
	Gross margin, %	—	—	—	—	(162.24)	(78.01)	13.31	43.12	45.70	49.79
	EBT	—	—	—	—	(23)	(65)	(73)	(44)	(41)	(36)
	EBT margin, %	—	—	—	—	(7,968.37)	(4,334.96)	(1,073.73)	(401.00)	(315.90)	(262.29)
	Net income	—	0	—	—	(23)	(65)	(73)	(44)	(41)	(36)
	Depreciation	—	—	—	—	0	1	1	1	1	1
Per share, $
Per share, $	Revenue	—	—	—	—	0.19	0.41	0.10	0.15	0.18	0.17
	Earnings	—	—	—	—	(15.38)	(17.57)	(1.04)	(0.62)	(0.56)	(0.43)
	Cash flow	—	—	—	—	(14.13)	(12.78)	(1.03)	(0.59)	(0.54)	(0.34)
	Capex	—	—	—	—	(1.03)	(0.73)	(0.01)	(0.01)	(0.01)	(0.01)
	Free cash flow	—	—	—	—	(15.16)	(13.52)	(1.04)	(0.60)	(0.54)	(0.36)
	Book value	—	—	—	—	(40.09)	50.45	1.76	1.18	0.68	0.50
	Shares, m	—	—	—	—	2	4	70	71	72	82
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	0.00	17.89	8.58	7.30	4.94	5.91
	P/B	—	—	—	—	12,839.40	0.14	0.47	0.95	1.30	1.95
	EV/Sales	—	—	—	—	0.00	(109.89)	(8.77)	0.43	2.02	3.25
	EV/FCF	—	—	—	—	0.00	3.30	0.82	(0.11)	(0.67)	(1.51)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	(22)	(47)	(72)	(42)	(39)	(28)
	Capex	—	—	—	—	(2)	(3)	(1)	(1)	0	(1)
	Free cash flow	—	—	—	—	(23)	(50)	(73)	(43)	(39)	(29)
Balance, $m
Balance, $m	Working capital	—	—	—	—	64	182	120	80	45	39
	Total debt	—	—	—	—	0	—	—	—	—	—
	Net debt	—	—	—	—	(64)	(191)	(118)	(76)	(38)	(36)
	Shareholders’ equity	—	—	—	—	(61)	186	124	84	49	41
Returns, %
Returns, %	ROA	—	—	—	—	(65.51)	(47.34)	(43.48)	(38.76)	(53.19)	(62.32)
	ROIC	—	—	—	—	0.00	0.00	(842.69)	(349.88)	(237.66)	(467.02)
	ROE	—	—	—	—	(37.43)	(103.62)	(47.21)	(42.51)	(61.03)	(79.01)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
APYX Apyx Medical Corporation	$107.8M	— (loss-making)	— (loss-making)	+22.08% (above 0%: growing)	n/m	−137.38% (below 0%: shrinking)	63.89%	(13.01%)	Compare
LUCD Lucid Diagnostics Inc.	$105.7M	— (loss-making)	— (loss-making)	+26.74% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	1.97%	(868.45%)	Compare
ZOMDF Zomedica Corp.	$95.4M	— (loss-making)	— (loss-making)	+36.59% (above 0%: growing)	n/m	+40.48% (above 0%: growing)	63.51%	(42.92%)	Compare
HYPR Hyperfine, Inc.	$82.7M	— (loss-making)	— (loss-making)	+44.81% (above 0%: growing)	n/m	+13.43% (above 0%: growing)	50.72%	(216.93%)
SERA Sera Prognostics, Inc.	$80.1M	— (loss-making)	— (loss-making)	+76.47% (above 0%: growing)	n/m	−10.58% (below 0%: shrinking)	(66.67%)	(33,346.67%)	Compare
LUNG Pulmonx Corporation	$79.5M	— (loss-making)	— (loss-making)	−4.62% (below 0%: shrinking)	n/m	−31.79% (below 0%: shrinking)	77.97%	(39.80%)	Compare
OM Outset Medical, Inc.	$76.6M	— (loss-making)	— (loss-making)	+0.69% (above 0%: growing)	n/m	−90.54% (below 0%: shrinking)	41.99%	(49.55%)	Compare
ECOR electroCore, Inc.	$75.3M	— (loss-making)	— (loss-making)	+28.03% (above 0%: growing)	n/m	−443.52% (below 0%: shrinking)	86.53%	(29.33%)	Compare
LNSR LENSAR, Inc.	$74.1M	2.0×	7.1×	+18.37% (above 0%: growing)	n/m	+96.81% (above 0%: growing)	59.27%	12.94%	Compare
Median of peers	$79.8M	—	—	+24.41%	—	−21.18%	61.39%	(41.36%)

All 149 Medical Devices stocks →

Hyperfine, Inc. (HYPR) key facts

Strength: Hyperfine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 5.22% from fiscal 2024.
Hyperfine, Inc. (HYPR) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, HYPR traded at $0.75, a market capitalization of $82.7 million.
Return on equity was −79.0% and debt-to-equity 0.36.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −6.11 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.